FRANKLIN, Mass., Dec. 17, 2010 /PRNewswire/ — Arthrosurface, Inc. (www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, announced that it has performed its first biological knee procedure based on the company’s proven HemiCAP® platform technology.
The next generation HemiCAP(BIO) implant is providing a biological scaffold with a cell-friendly surface environment that is supported by a stable, contoured implant.
Arthroscopic cartilage procedures have been targeting bone marrow cells for focal cartilage repair for over two decades. “We are excited to combine our focal HemiCAP® resurfacing technology with the cellular healing response achieved by bone marrow influx,” commented Steven Ek, COO.
The technology provides a load sharing matrix that has shown to provide complete biological surface coverage in preclinical tests, said Matthias Schurhoff, MD, VP of Clinical Operations and Scientific Affairs.
Dr. Willem van der Merwe, Sport Science Centre of South Africa, performed the first bio HemiCAP® surgery and has more than five years of experience with the classic HemiCAP® procedure: “I am very satisfied with the follow-up on my previous patients and observed a remarkable return to sports activities. Now, we look forward to assessing the clinical performance criteria for the new bio surface.”
The HemiCAP® implant for the femoral condyle is targeting middle aged patients with weight bearing full thickness defects who continue to suffer from knee pain.
Joint preservation is critical for the long term management of knee arthritis. Focal HemiCAP® resurfacing expands reconstructive treatment options intended to delay traditional arthroplasty for patients. In contrast to conventional joint replacement, the company’s resurfacing technology allows the surgeon to precisely mill the surface to cover the defect and fit the implant to the patient while preserving healthy cartilage, bone, and soft tissues.
“Arthrosurface continuous to grow its platform to address early and late stage knee arthritis,” said Steven Tallarida, President, who observed the first HemiCAP(BIO) implantation.
The system currently offers over 140 different sizes and shapes to effectively treat cartilage defects in a large variety of joints by recreating the patient’s joint geometry with an intraoperative 3-D mapping system.
SOURCE Arthrosurface, Inc.
